インタビュー
「Oral Abstract Session:小児癌II」の座長 Terzah M. Horton氏に聞く
本セッションは小児癌の中で最も多い癌のひとつである神経芽細胞腫の治療をテーマに行われた。神経芽細胞腫発生に深く関わっていることが指摘されている変異ALK(未分化リンパ腫キナーゼ)およびその阻害剤など,新たな治療法や治療ターゲットに関する報告が相次ぎ,熱心な討議が行われた。その座長を務めたTerzah M. Horton氏(ベイラー医科大学)にセッション終了後,話を聞いた。(佐藤生美雄)
編集部 | まだ初期段階の各種治療法の研究結果が報告されましたが,先生は今,小児癌治療はどの方向に向かっているとお考えですか? |
Horton氏 |
Get the Flash Player to see this player.
|
Download(クリックで保存) |
targeted agents:(分子)標的薬
pediatric cancer:小児癌
survival curves:生存曲線
So, we're moving more towards the use of targeted agents. We really have gotten as much out of sighted toxic agents as really we're going to, and pediatric cancer as evidenced by the flattening off of survival curves. So, now it's going to be very important to incorporate new agents that are more targeted towards things that are defective in children's cancers.
編集部 | 今年のASCOについて,感想をお聞かせください。 |
Horton氏 |
Get the Flash Player to see this player.
|
Download(クリックで保存) |
new agents:新薬
development:開発
Oh, ASCO's an exciting meeting. I think this year there's been a lot of new agents presented, and a lot of these agents are potentially relevant for children. So, it's an exciting time and we look forward to these development - to the development of these agents in children.
編集部 | 最後に,日本のドクターへのメッセージをいただけますか? |
Horton氏 |
Get the Flash Player to see this player.
|
Download(クリックで保存) |
a great deal:ずいぶんと
advancement:発展
We want to encourage everyone throughout the planet to continue working on these agents. The Japanese have contributed a great deal to the advancement of new drugs, and we want to encourage them to - on their work.